Institution: Genexine ESMO 2022 | The promising efficacy of GX-188E vaccine + pembro vs pembro alone in HPV+ cervical cancer

Neil Warma, MBA, Genexine, Inc, Seoul, Republic of Korea, provides an overview of the Phase II (NCT03444376) trial investigating the efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer. GX-188E vaccine combined with pembrolizumab in advanced cervical cancer was safe and tolerable, and showed significant efficacy compared with pembrolizumab alone. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.